PUBLICATION:
Nature. 2002 Jan 31;415(6871):530-6.

AUTHORS:
van ‘t Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H.

SUMMARY:
Development of MammaPrint from 98 tumors, to 78 (non-BRCA). his gene expression profile will outperform all currently used clinical parameters in predicting disease outcome. Our findings provide a strategy to select patients who would benefit from adjuvant therapy.

Read more: Gene Expression… van ‘t Veer LJ et al_Nature 2002